证券代码：301087 证券简称：可孚医疗 公告编号：2022-045 可孚医疗科技股份有限公司 关于参加湖南辖区上市公司2022年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步增强与广大投资者的互动交流，可孚医疗科技股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员湖南监管局、湖南省上市公司协 会与深圳市全景网络有限公司联合举办的"湖南辖区上市公司 2022 年投资者网 上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台，采取网络远程的方式举行，投资者可以登录"全景路演"网站 （http://rs.p5w.net）参与公司本次投资者接待日活动，活动时间为 2022 年 9 月 29 日（星期四）15:30-16:55。 届时公司董事会秘书、证券事务代表及相关工作人员将通过网络在线交流的 形式与投资者进行沟通与交流。欢迎广大投资者积极参与。 特此公告。 可孚医疗科技股份有限公司董事会 2022 年 9 月 23 日 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[22]. - The company has set a revenue guidance of RMB 1.2 billion for the full year 2022, indicating a projected growth of 15% compared to 2021[22]. - The company's operating revenue for the current period is ¥1,295,832,098.62, representing a 17.84% increase compared to ¥1,099,625,251.47 in the same period last year[30]. - Net profit attributable to shareholders decreased by 39.60% to ¥130,236,840.62 from ¥215,608,899.95 in the previous year[30]. - The net profit after deducting non-recurring gains and losses fell by 53.86% to ¥89,409,549.24 from ¥193,798,650.08 year-on-year[30]. - The net cash flow from operating activities was negative at -¥78,209,578.33, a decline of 171.07% compared to ¥110,038,734.22 in the previous year[30]. - Basic earnings per share decreased by 55.07% to ¥0.62 from ¥1.38 in the same period last year[30]. - The company achieved operating revenue of CNY 1,295.83 million in the first half of 2022, representing a year-on-year growth of 17.84%[91]. - In Q2 2022, the operating revenue reached CNY 695.08 million, marking a significant increase of 53.74% compared to the same period last year[91]. - The net profit attributable to the parent company was CNY 130.24 million, a decrease of 39.60% year-on-year, with Q2 net profit at CNY 80.03 million, down 6.10% year-on-year[91]. Product Development and Innovation - New product launches included a state-of-the-art glucose monitoring device, expected to contribute an additional RMB 100 million in revenue by the end of 2022[22]. - The company focuses on product innovation and has a diverse product line covering health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy[41]. - The company is actively pursuing new product development, including a COVID-19 antigen home test authorized for OTC use[71]. - The company has introduced new medical devices, including a medical cotton and a blood glucose test strip, with registration certificates valid until January 17, 2027, and May 21, 2025, respectively[72]. - The company is focusing on the development of new technologies, including rapid testing methods for various diseases, enhancing its market competitiveness[75]. - The company aims to leverage real-time fluorescence quantitative PCR technology across its product offerings, improving the accuracy and speed of diagnostics[20][28]. - The product portfolio includes tests for both high-risk and low-risk HPV types, addressing a significant area in women's health diagnostics[18][19]. - The company is committed to providing comprehensive diagnostic solutions, with a focus on infectious diseases and conditions requiring molecular testing[27][31]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[22]. - The company has completed the layout of major third-party e-commerce platforms, including Tmall, JD.com, and Pinduoduo, with 82 self-operated stores, enhancing its online consumer reach[52]. - The company has plans for market expansion, particularly in the field of in vitro diagnostics, to capture a larger share of the healthcare market[75]. - The company is focusing on increasing the proportion of self-produced products and enhancing online and offline sales channels[150]. - The company has established a multi-channel marketing strategy, including large e-commerce platforms and chain pharmacies, to enhance market penetration[89]. Research and Development - Research and development expenses increased by 30% to RMB 50 million, reflecting the company's commitment to innovation[22]. - The company emphasizes R&D investment and collaboration with research institutions to enhance its core technology and accelerate product upgrades[46]. - The company has established a mature R&D system and comprehensive quality control system, enhancing brand recognition and market reputation[65]. - The company plans to enhance R&D capabilities and optimize product structure to ensure continued growth in the medical device market[142]. - The company is committed to ongoing research and development to innovate and improve its product offerings in the healthcare sector[77]. Acquisitions and Partnerships - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of RMB 200 million allocated for this purpose[22]. - The company completed the acquisition of Acorn Trade and Chengdu Yier, enhancing its industry chain layout[98]. - The company acquired a 80% stake in Sichuan Jianer Hearing Aid Co., Ltd. for CNY 17,440,000.00, which has been completed[116]. - The company also completed the acquisition of Acorn Trading (Shanghai) Co., Ltd. for CNY 175,250,000.00, holding a 100% stake[116]. - The company is actively integrating the acquisitions of Bei Bei Jia and Ji Rui Medical, with plans for future acquisitions in the hearing business[150]. Risk Management - The company identified potential risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[6]. - The company faces risks from intensified industry competition and aims to enhance technological R&D and smart manufacturing to maintain competitive advantages[143]. - The company emphasizes the importance of optimizing management systems to mitigate operational risks as it expands its business scale[144]. - The company has conducted multiple investor communications regarding R&D focus, product integration, and future growth plans[148]. Corporate Governance and Social Responsibility - The company has established a robust corporate governance structure to ensure compliance with relevant laws and regulations[168]. - The company emphasizes its commitment to social responsibility, focusing on healthcare, education support, and rural revitalization initiatives[167]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[165]. - The company has received various honors, including being listed among the top 100 most influential pharmaceutical companies in China[65]. Operational Efficiency - The company has developed a digital operation support system that enhances overall operational efficiency and quality control[90]. - The company has established a comprehensive supplier evaluation system to achieve win-win cooperation along the industrial chain[173]. - The company has built a multi-channel marketing strategy, including large e-commerce platforms and chain pharmacies, to enhance market penetration[89].

Financial Performance - Revenue for Q1 2022 was ¥600,753,831.09, a decrease of 7.22% compared to ¥647,521,779.69 in the same period last year[4] - Net profit attributable to shareholders was ¥50,204,732.44, down 61.49% from ¥130,373,181.25 year-on-year[4] - Basic earnings per share decreased by 71.19% to ¥0.3130 from ¥1.0864 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 600,753,831.09, a decrease of 7.5% compared to CNY 647,521,779.69 in the same period last year[28] - The net profit for Q1 2022 was CNY 52,632,513.24, a decrease of 59.6% compared to CNY 130,467,736.06 in Q1 2021[30] - The company reported a net profit margin of approximately 10.7% for Q1 2022, down from 12.5% in Q1 2021[28] - Operating profit for Q1 2022 was CNY 59,566,256.94, down 63.1% from CNY 161,416,685.71 in Q1 2021[30] - The company reported a total comprehensive income of CNY 52,632,513.24 for Q1 2022, down from CNY 130,467,736.06 in the previous year[34] Cash Flow and Liquidity - Net cash flow from operating activities was negative at ¥317,768,933.80, a significant decline of 4,479.79% compared to ¥7,255,348.97 in the same period last year[4] - Total operating cash flow was negative at approximately -¥317.77 million, a decrease of 4479.79% compared to the previous period, primarily due to increased procurement costs[10] - The cash flow from operating activities showed a net outflow of CNY 317,768,933.80, compared to a net inflow of CNY 7,255,348.97 in Q1 2021[39] - Cash and cash equivalents decreased to CNY 1,795,982,502.52 from CNY 1,989,232,177.59 at the beginning of the year, a decline of 9.7%[25] - The total cash and cash equivalents at the end of Q1 2022 were CNY 1,730,252,830.26, down from CNY 2,213,913,015.86 at the end of Q1 2021[39] - Financing activities generated a net cash inflow of CNY 273,675,360.54, contrasting with a net outflow of CNY 176,044,056.53 in Q1 2021[39] Assets and Liabilities - Total assets increased by 5.95% to ¥6,152,439,179.75 from ¥5,807,122,186.75 at the end of the previous year[4] - Total liabilities increased to CNY 1,128,556,091.80, a rise of 34.0% from CNY 841,974,541.55 at the start of the year[27] - The company's equity attributable to shareholders rose to CNY 5,004,378,974.99, an increase of 1.2% from CNY 4,947,205,854.71 at the beginning of the year[27] - Non-current assets totaled CNY 1,598,040,668.38, a significant increase of 24.0% from CNY 1,288,258,012.57 at the start of the year[25] Expenses - Total operating costs increased to CNY 536,028,236.07, up 10.2% from CNY 486,315,695.66 in Q1 2021[28] - Sales expenses rose by 30.29% to approximately ¥124.68 million, driven by significant expansion in the hearing aid segment and the acquisition of Jirui Medical[10] - R&D expenses increased by 75.78% to approximately ¥21.10 million, attributed to a rise in personnel and project costs[10] - Research and development expenses increased to CNY 21,100,488.96, up 76% from CNY 12,003,648.26 in the previous year[30] - The company’s management expenses surged by 141.55% to approximately ¥28.21 million, largely due to stock payment expenses and the acquisition of Jirui Medical[10] Acquisitions and Investments - The company acquired 80% of Chengdu Yier Hearing Aid Co., Ltd. for RMB 17.44 million, which has been included in the consolidated financial statements[21] - The company completed the acquisition of 100% of Acorn Trading (Shanghai) Co., Ltd. for RMB 177 million, including related intellectual property rights, and it is now a wholly-owned subsidiary[21] - The company is actively pursuing strategic acquisitions to enhance its market position and expand its product offerings[21] Shareholder Information - The total number of restricted stock granted under the 2021 incentive plan was 375,000 shares, increasing the total share capital from 160 million to 160.375 million shares[21] - The company reported a total of 123,426,040 restricted shares at the end of the reporting period[19] - The top ten shareholders hold a significant portion of unrestricted shares, with the largest being China Construction Bank's fund holding 1,612,897 shares[17] - The company has a total of 65,446,095 restricted shares held by Changsha Medical Investment Co., Ltd., which will be released on April 24, 2025[17] - The company’s major shareholders include Zhang Min and Nie Juan, who collectively control a significant portion of the company[17] - The company has not reported any changes in the number of restricted shares during the reporting period[19] - The company’s stock is subject to various restrictions, with specific release dates for different shareholders[17] Other Financial Metrics - Non-operating income totaled ¥1,870,282.45 after accounting for tax effects and minority interests[5] - The weighted average return on equity decreased by 11.33 percentage points to 1.01% from 12.34%[4] - Deferred income tax liabilities increased by 37.73% to approximately ¥6.01 million, due to temporary differences from fair value changes in financial assets[10] - The company reported a significant increase in investment income of 529.58% to approximately ¥1.49 million, resulting from gains on structured deposits[10]

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 25% in 2021 compared to 2020 [19]. - The company's operating revenue for 2021 was ¥2,275,632,827.25, a decrease of 4.19% compared to ¥2,375,260,698.66 in 2020 [24]. - The net profit attributable to shareholders for 2021 was ¥428,856,562.39, reflecting a slight increase of 1.16% from ¥423,949,885.67 in 2020 [24]. - The net cash flow from operating activities decreased significantly by 51.59% to ¥239,990,590.88 from ¥495,768,010.28 in 2020 [24]. - The total assets at the end of 2021 amounted to ¥5,807,122,186.75, representing a 223.59% increase from ¥1,794,566,648.21 at the end of 2020 [24]. - The net assets attributable to shareholders increased by 396.50% to ¥4,947,205,854.71 from ¥996,417,687.46 in 2020 [24]. - The basic earnings per share for 2021 was ¥3.39, down 3.97% from ¥3.53 in 2020 [24]. - The weighted average return on equity for 2021 was 23.91%, a decrease of 29.19 percentage points from 53.10% in 2020 [24]. - The company achieved a total revenue of 2,275.63 million CNY in 2021, a decrease of 4.19% compared to the previous year, but a growth of 55.65% compared to 2019 [67]. - The net profit attributable to the parent company was 428.86 million CNY, an increase of 1.16% year-on-year and a growth of 246.73% compared to 2019 [67]. Dividend Distribution - The company plans to distribute a cash dividend of 16.00 RMB per 10 shares to all shareholders, based on a total of 160,375,000 shares [6]. Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in the medical device sector, with plans to enter new geographical markets [19]. - The company anticipates a revenue growth target of 20% for the upcoming fiscal year, driven by increased demand for its medical devices [19]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings [19]. - The company has established partnerships with over 60 major chain pharmacies, enhancing its distribution network [61]. - The company is actively pursuing overseas market expansion, including cross-border e-commerce, to increase its international business scale [165]. Research and Development - The company is investing in research and development for new medical technologies, aiming to launch at least three new products in the next fiscal year [19]. - The company has established three research institutes focusing on medical electronics, rehabilitation medicine, and biosensing, enhancing its R&D capabilities [58]. - The company invested 70.59 million CNY in R&D, a year-on-year increase of 59.47%, with a total of 264 R&D personnel, reflecting a growth of 104.65% [71]. - The company has launched several new products, including blood glucose meters and rapid test kits, contributing significantly to revenue growth [71]. - The company is focused on high-quality development through R&D innovation and self-production [97]. - The company aims to enhance its R&D capabilities by increasing investment in R&D platforms and collaborating with universities and medical institutions to drive product innovation [155]. Product Development and Offerings - The company has a diverse product line covering health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine, with nearly 10,000 product models and specifications [64]. - The company is expanding its product offerings with a range of hearing aids, including smart and in-ear models, expected by December 2025 [106]. - The company is enhancing its product portfolio with a variety of medical devices, including a nasal irrigator and a blood glucose and pressure testing device [106]. - The company is developing a human chorionic gonadotropin (HCG) test kit for qualitative detection in urine [106]. - The company is expanding its product line with a glucose quality control solution for blood glucose testing [106]. Operational Efficiency - The company has outlined a strategic plan to enhance its supply chain efficiency, which is expected to reduce operational costs by approximately 10% [19]. - The company has implemented a production model based on "sales-driven production" to ensure quality and timely delivery while effectively reducing inventory [60]. - The company is committed to improving its quality management system across all stages, from R&D to after-sales service, to enhance product quality and production efficiency [164]. Risk Management - The company has identified potential risks in its operational strategy and has developed mitigation plans to address these challenges [6]. - The company is managing acquisition risks by strengthening operational management and strategic coordination with acquired companies to support their business growth [171]. - The company is addressing risks related to the COVID-19 pandemic by adjusting its production strategies and expanding its product offerings to maintain growth [168]. Governance and Shareholder Engagement - The governance structure of the company is compliant with relevant laws and regulations, ensuring a high level of operational integrity [178]. - The company has maintained a strong focus on shareholder rights and engagement, ensuring all shareholders can exercise their rights effectively [179]. - The company has established an independent financial department with a complete financial accounting system, allowing for autonomous financial decision-making [188]. - The company held its annual general meeting with 100% investor participation, discussing key reports and financial plans [192]. Future Outlook - The company plans to achieve a sales revenue growth of no less than 30% in 2022 compared to the previous year [165]. - Future development plans include new product launches and ongoing research and development efforts to enhance product offerings [175]. - The company aims to enhance its market expansion efforts by optimizing its marketing network and strengthening its sales team [165].

可孚医疗科技股份有限公司 2021 年第三季度报告 证券代码：301087 证券简称：可孚医疗 公告编号：2021-010 可孚医疗科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|----------------|-------------------------|--------------------------|-------- ...